{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.22","value":"7.3"},{"groupId":"OG001","spread":"2.89","value":"13.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Anti-HPV-16 (Week 15)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.24","value":"9.6"},{"groupId":"OG001","spread":"3.07","value":"15.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Anti-HPV-16 (Week 27)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.33","value":"15.9"},{"groupId":"OG001","spread":"3.06","value":"17.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Anti-HPV-16 (Week 48)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.31","value":"14.5"},{"groupId":"OG001","spread":"2.80","value":"6.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Anti-HPV-16 (Week 74)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.13","value":"37.0"},{"groupId":"OG001","spread":"2.85","value":"11.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Anti-HPV-16 (Week 96)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.73","value":"24.8"},{"groupId":"OG001","spread":"4.32","value":"133.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Anti-HPV-18 (Week 15)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.67","value":"44.7"},{"groupId":"OG001","spread":"4.85","value":"89.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Anti-HPV-18 (Week 27)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.87","value":"69.3"},{"groupId":"OG001","spread":"4.36","value":"133.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Anti-HPV-18 (Week 48)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.98","value":"83.2"},{"groupId":"OG001","spread":"4.23","value":"45.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Anti-HPV-18 (Week 74)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.86","value":"2.9"},{"groupId":"OG001","spread":"1.61","value":"2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Anti-HPV-18 (Week 96)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with histologically confirmed vulvar HSIL associated with HPV-16 and/or 18, received four doses of 6 mg VGX-3100 as an IM injection on Day 0, Week 4, Week 12, and Week 24 followed by EP using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52.","id":"OG000","title":"VGX-3100 + EP"},{"description":"Participants with histologically confirmed vulvar HSIL associated with HPV-16 and/or 18, received four doses of 6 mg VGX-3100 as an IM injection on Day 0, Week 4, Week 12, and Week 24 followed by EP using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52. In addition, participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.","id":"OG001","title":"VGX-3100 + EP + Imiquimod"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"mITT population included all participants who received at least 1 dose of VGX-3100 + EP (with or without imiquimod) and had an analysis endpoint of interest. 'Overall number of participants analyzed' indicates the number of participants with data available for outcome measure analysis. 'Number analyzed' indicates the number of participants available for analysis at individual time points.","reportingStatus":"POSTED","timeFrame":"Weeks 15, 27, 48, 74, and 96","title":"Levels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations","type":"SECONDARY","unitOfMeasure":"reciprocal endpoint titer"}